Correlation of serum FGF1 expression with glucose and lipid metabolism in bipolar disorder

doi:10.3969/j.issn.1004-583X.2025.07.006

Abstract

Abstract:

Objective To study serum level of fibroblast growth factor 1 (FGF1) and the correlation with glucose and lipid metabolism in patients with stable bipolar disorder (BD). Methods A total of 110 patients with stable BD under the management of community health service centers from March 2024 to December 2024 were selected as the study objects, involving 52 patients in the bipolar disorder medication group (BD-M), and 58 in the bipolar disorder no medication group (BD-NM). During the same period, 60 healthy volunteers receiving physical examinations were selected as the control group. Serum FGF1 level and glucose and lipid metabolism were measured and compared. The correlation of FGF1 with glucose and lipid metabolism was analyzed. Results Blood glucose was significantly higher in the BD-NM group and BD-M group than the control group, while the high-density lipoprotein cholesterol (HDL-C) was significantly lower (all P<0.05). Compared to the control group, triglycerides (TG), cholesterol (CHOL), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A (ApoA), apolipoprotein B (ApoB) and lipoprotein a (LPa) were significantly higher in the BD-M group (all P<0.05), while the total protein (TP) was significantly lower (P<0.01). TG, CHOL, ApoA, ApoB and LPa in the BD-M group were significantly higher than the BD-NM group (all P<0.05), while TP was significantly lower (P<0.05). The highest serum FGF1 was found in the BD-M group, followed by BD-NM group and control group (P<0.05). Spearman Correlation analysis showed that serum FGF1 levels in the BD-M group were positively correlated with blood glucose, TG, CHOL, LDL-C and ApoB (all P<0.05), but negatively correlated with TP (P<0.05). Conclusion Increase serum FGF1 in BD patients is correlated with medication-induced glucose and lipid metabolism disorders, and FGF1 may be used to monitor or prevent metabolic abnormalities induced by psychotropic drugs.

Key words: bipolar disorder, fibroblast growth factor 1, peripheral blood, glucose and lipid metabolism parameters, psychotropic medication treatment

CLC Number:

R749.4

Lu Yuansi, Lv Jianjun, Guan Jibin, Cao Longbin. Correlation of serum FGF1 expression with glucose and lipid metabolism in bipolar disorder[J]. Clinical Focus, 2025, 40(7): 619-623.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.07.006

http://www.lchc.cn/EN/Y2025/V40/I7/619

Figures/Tables 4

References 22

[1]	Carvalho AF, Firth J, Vieta E. Bipolar Disorder[J]. N Engl J Med, 2020, 383(1):58-66.
[2]	Nierenberg AA, Agustini B, Köhler-Forsberg O, et al. Diagnosis and treatment of bipolar disorder: A review[J]. JAMA, 2023, 330(14):1370-1380. doi: 10.1001/jama.2023.18588 pmid: 37815563
[3]	IsHak WW, Brown K, Aye SS, et al. Health-related quality oflife in bipolar disorder[J]. Bipolar Disord, 2012, 14(1):6-18.
[4]	Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Networkfor Mood and Anxiety Treatments(CANMAT) and InternationalSociety for Bipolar Disorders (ISBD) 2018 guidelines for themanagement of patients with bipolar disorder[J]. Bipolar Disord, 2018, 20(2):97-170.
[5]	Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, et al. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders[J]. Cytokine Growth Factor Rev, 2016,32:85-96.
[6]	Greenhill C. FGF1 signalling cascade suppresses lipolysis[J]. Nat Rev Endocrinol, 2022, 18(3):135.
[7]	姬卫秀, 李萌, 赵云罡. 基于成纤维细胞生长因子1的药物治疗肥胖相关并发症[J]. 生物化学与生物物理进展, 2024, 51(6):1341-1356.
[8]	张明园, 何燕玲. 精神科评定量表手册[M]. 长沙: 湖南科学技术出版社, 2015: 128-328.
[9]	Rush AJ, Bernstein IH, Trivedi MH, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: A sequenced treatment alternatives to relieve depression trial report[J]. Biol Psychiatry, 2006, 59(6):493-501.
[10]	Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness[J]. Nat Rev Cardiol, 2021, 18(2):136-145. doi: 10.1038/s41569-020-00463-7 pmid: 33128044
[11]	Goldfarb M, De Hert M, Detraux J, et al. Severe mental illness and cardiovascular disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 80(9):918-933. doi: 10.1016/j.jacc.2022.06.017 pmid: 36007991
[12]	沈阿姿, 孙静. 双相障碍共病躯体疾病的研究进展[J]. 中华精神科杂志, 2020, 53(6):537-541.
[13]	崔东红. 双相障碍的代谢障碍及相关发病机制[J]. 中华精神科杂志, 2022, 55(3) :175-181.
[14]	Kalelioglu T, Genc A, Karamustafalioglu N, et al. Assessment of cardiovascular risk via atherogenic indices in patients with bipolar disorder manic episode and alterations with treatment[J]. Diabetes Metab Syndr, 2017, 11(Suppl 1):S473-S475.
[15]	Nihalani N, Schwartz TL, Siddiqui UA, et al. Obesity and psychotropics CNS neurosci[J]. Ther, 2020, 8(1):57-63.
[16]	Luo H, Jiang ZL, Ren Y. Therapy management of metabolic disorder comorbidity with depression[J]. Front Psychol, 2021,12:683320.
[17]	Suh JM, Jonker JW, Ahmadian M, et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer[J]. Nature, 2014, 513(7518):436-439.
[18]	Sancar G, Liu S, Gasser E, et al. FGF1 and insulin control lipolysis by convergent pathways[J]. Cell Metab, 2022, 34(1):171-183.e6. doi: 10.1016/j.cmet.2021.12.004 pmid: 34986332
[19]	Wang J, Zhang F, Yang W, et al. FGF1 ameliorates obesity-associated hepatic steatosis by reversing IGFBP2 hypermethylation[J]. FASEB J, 2023, 37(4):e22881.
[20]	Perry RJ, Lee S, Ma L, et al. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis[J]. Nat Commun, 2015, 6:6980. doi: 10.1038/ncomms7980 pmid: 25916467
[21]	Zhao Y, Ye S, Lin J, et al. Corrigendum: NmFGF1-regulated glucolipid metabolism and angiogenesis improves functional recovery in a mouse model of diabetic stroke and acts via the AMPK signaling pathway[J]. Front Pharmacol, 2024, 15:1392148.
[22]	Kao CY, Hsu YC, Liu JW, et al. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities[J]. J Neurochem, 2013, 126(1):4-18.

项目	HC(n=60)	BD-NM(n=58)	BD-M(n=52)	F/χ²/Z值	P值
年龄(岁)	38(35,45)	39(35,47)	39(35,47)	0.810	0.447
男/女[例(%)]	28(47.0)/32(53.0)	27(46.5)/31(52.5)	29(55.8)/23(44.2)	1.210	0.546
BMI	22.61±3.04	23.79±3.83	23.81±3.70	2.232	0.111
SBP(mmHg)	123.9±19.27	131.86±15.01	129.21±15.29	1.135	0.324
DBP(mmHg)	78.33±1.28	77.75±8.34	79.52±5.36	3.845	0.069

项目	HC(n=60)	BD-NM(n=58)	BD-M(n=52)	F/χ²/Z值	P值
年龄(岁)	38(35,45)	39(35,47)	39(35,47)	0.810	0.447
男/女[例(%)]	28(47.0)/32(53.0)	27(46.5)/31(52.5)	29(55.8)/23(44.2)	1.210	0.546
BMI	22.61±3.04	23.79±3.83	23.81±3.70	2.232	0.111
SBP(mmHg)	123.9±19.27	131.86±15.01	129.21±15.29	1.135	0.324
DBP(mmHg)	78.33±1.28	77.75±8.34	79.52±5.36	3.845	0.069

项目	HC(n=60)	BD-NM(n=58)	BD-M(n=52)	F/Z值	P值
GLU(mmol/L)	4.82(4.50,5.18)	5.45(4.97,6.33)^△	5.81(4.55,6.58)^△	12.59	<0.01
TG(mmol/L)	1.13(0.90,1.62)	1.42(0.97,2.32)	2.33(1.70,3.26)^△▲	25.17	<0.01
CHOL(mmol/L)	5.31(4.74,6.28)	5.26(4.40,6.00)	6.47(5.29,7.71)^△▲	13.18	<0.01
HDL-C(mmol/L)	1.54±0.32	1.36±0.34^△	1.32±0.88^△	8.79	<0.01
LDL-C(mmol/L)	3.08±0.79	3.34±0.88	3.48±0.95^*	3.07	0.039
APO-A(g/L)	1.41(1.33,1.49)	1.35(1.32,1.51)	1.89(1.79,1.98)^△▲	115.30	<0.01
APO-B(g/L)	1.07(1.03,1.11)	1.04(0.84,1.11)	1.37(1.17,1.64)^△▲	34.67	<0.01
LPa(mg/dl)	7.60(5.27,9.32)	8.70(4.00,16.15)	10.2(8.25,11.95)^△#	15.25	<0.01
TP(g/L)	69.06±12.13	65.82±8.47	61.38±5.85^△#	9.48	<0.01
ALB(g/L)	36.20±5.29	37.47±7.39	33.63±6.07	2.23	0.106
ALT(U/L)	16.50(13.00,22.75)	17.00(12.59,23.68)	17.21(9.87,24.21)	0.10	0.905
AST(U/L)	23.00(20.25,27.01)	23.12(20.00,27.25)	22.36(20.21,29.36)	0.28	0.758
CR(μmol/L)	67.65(57.67,79.87)	72.90(57.52,91.47)	74.8(66.47,83.95)	2.16	0.118
UREA(mmol/L)	5.66(4.59,6.46)	5.79(4.63,6.89)	5.73(4.81,6.94)	0.10	0.902
UA(μmol/L)	323.01(294.24,401.14)	359.82(286.25,426.75)	358.48(270.25,414.51)	2.70	0.069

项目	HC(n=60)	BD-NM(n=58)	BD-M(n=52)	F/Z值	P值
GLU(mmol/L)	4.82(4.50,5.18)	5.45(4.97,6.33)^△	5.81(4.55,6.58)^△	12.59	<0.01
TG(mmol/L)	1.13(0.90,1.62)	1.42(0.97,2.32)	2.33(1.70,3.26)^△▲	25.17	<0.01
CHOL(mmol/L)	5.31(4.74,6.28)	5.26(4.40,6.00)	6.47(5.29,7.71)^△▲	13.18	<0.01
HDL-C(mmol/L)	1.54±0.32	1.36±0.34^△	1.32±0.88^△	8.79	<0.01
LDL-C(mmol/L)	3.08±0.79	3.34±0.88	3.48±0.95^*	3.07	0.039
APO-A(g/L)	1.41(1.33,1.49)	1.35(1.32,1.51)	1.89(1.79,1.98)^△▲	115.30	<0.01
APO-B(g/L)	1.07(1.03,1.11)	1.04(0.84,1.11)	1.37(1.17,1.64)^△▲	34.67	<0.01
LPa(mg/dl)	7.60(5.27,9.32)	8.70(4.00,16.15)	10.2(8.25,11.95)^△#	15.25	<0.01
TP(g/L)	69.06±12.13	65.82±8.47	61.38±5.85^△#	9.48	<0.01
ALB(g/L)	36.20±5.29	37.47±7.39	33.63±6.07	2.23	0.106
ALT(U/L)	16.50(13.00,22.75)	17.00(12.59,23.68)	17.21(9.87,24.21)	0.10	0.905
AST(U/L)	23.00(20.25,27.01)	23.12(20.00,27.25)	22.36(20.21,29.36)	0.28	0.758
CR(μmol/L)	67.65(57.67,79.87)	72.90(57.52,91.47)	74.8(66.47,83.95)	2.16	0.118
UREA(mmol/L)	5.66(4.59,6.46)	5.79(4.63,6.89)	5.73(4.81,6.94)	0.10	0.902
UA(μmol/L)	323.01(294.24,401.14)	359.82(286.25,426.75)	358.48(270.25,414.51)	2.70	0.069

指标	BD-NM(n=58)		BD-M(n=52)
	FGF1		FGF1
		r值	P值	r值	P值
BMI	0.196	0.141	-0.127	0.370
SDP(mmHg)	-0.167	0.209	-0.02	0.889
BDP(mmHg)	-0.174	0.191	0.017	0.902
GLU(mmol/L)	0.115	0.389	0.834	<0.01
TG(mmol/L)	-0.031	0.814	0.735	<0.01
CHOL(mmol/L)	0.15	0.26	0.727	<0.01
HDL-C(mmol/L)	-0.122	0.361	0.261	0.062
LDL-C(mmol/L)	-0.077	0.563	0.523	<0.01
APO-A(g/L)	0.092	0.494	0.217	0.122
APO-B(g/L)	-0.163	0.223	0.293	0.035
LPa(mg/dL)	0.074	0.58	0.234	0.096
TP(g/L)	0.161	0.226	-0.417	0.002
ALB(g/L)	-0.015	0.912	0.03	0.831
ALT(U/L)	0.182	0.172	-0.104	0.464
AST(U/L)	0.256	0.052	-0.167	0.235
CR(μmol/L)	0.218	0.101	-0.035	0.803
UREA(mmol/L)	0.035	0.793	0.028	0.842
UA(μmol/L)	-0.021	0.874	0.012	0.930